scispace - formally typeset
Open AccessJournal ArticleDOI

Amyloid-β peptide protects against microbial infection in mouse and worm models of Alzheimer’s disease

Reads0
Chats0
TLDR
In vivo data showing that Aβ expression protects against fungal and bacterial infections in mouse, nematode, and cell culture models of AD are presented, and Aβ oligomerization, a behavior traditionally viewed as intrinsically pathological, may be necessary for the antimicrobial activities of the peptide are shown.
Abstract
The amyloid-β peptide (Aβ) is a key protein in Alzheimer’s disease (AD) pathology. We previously reported in vitro evidence suggesting that Aβ is an antimicrobial peptide. We present in vivo data showing that Aβ expression protects against fungal and bacterial infections in mouse, nematode, and cell culture models of AD. We show that Aβ oligomerization, a behavior traditionally viewed as intrinsically pathological, may be necessary for the antimicrobial activities of the peptide. Collectively, our data are consistent with a model in which soluble Aβ oligomers first bind to microbial cell wall carbohydrates via a heparin-binding domain. Developing protofibrils inhibited pathogen adhesion to host cells. Propagating β-amyloid fibrils mediate agglutination and eventual entrapment of unatttached microbes. Consistent with our model, Salmonella Typhimurium bacterial infection of the brains of transgenic 5XFAD mice resulted in rapid seeding and accelerated β-amyloid deposition, which closely colocalized with the invading bacteria. Our findings raise the intriguing possibility that β-amyloid may play a protective role in innate immunity and infectious or sterile inflammatory stimuli may drive amyloidosis. These data suggest a dual protective/damaging role for Aβ, as has been described for other antimicrobial peptides.

read more

Citations
More filters
Journal ArticleDOI

Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders

TL;DR: This Review discusses neuroimaging studies in the living human brain and post-mortem tissue as well as biomarker studies demonstrating BBB breakdown in Alzheimer disease, Parkinson disease, Huntington disease, amyotrophic lateral sclerosis, multiple sclerosis, HIV-1-associated dementia and chronic traumatic encephalopathy.
Journal ArticleDOI

Alzheimer Disease: An Update on Pathobiology and Treatment Strategies.

TL;DR: Recent advances in the understanding of AD pathobiology are reviewed and current treatment strategies are discussed, highlighting recent clinical trials and opportunities for developing future disease-modifying therapies.
Journal ArticleDOI

How neuroinflammation contributes to neurodegeneration.

TL;DR: Observations indicate that therapies targeting glial cells might provide benefit for those afflicted by neurodegenerative disorders, because the environment is affected during disease in a cascade of processes collectively termed neuroinflammation.
References
More filters
Journal ArticleDOI

Diffusible, nonfibrillar ligands derived from Aβ1–42 are potent central nervous system neurotoxins

TL;DR: It is hypothesized that impaired synaptic plasticity and associated memory dysfunction during early stage Alzheimer's disease and severe cellular degeneration and dementia during end stage could be caused by the biphasic impact of Abeta-derived diffusible ligands acting upon particular neural signal transduction pathways.
Journal ArticleDOI

Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective.

TL;DR: The amyloid hypothesis based on both known and putative Alzheimer's disease genes is assessed, with positive results for beta-amyloid inaques andaques is confirmed in animals and humans.
Journal ArticleDOI

The Systemic Amyloidoses

TL;DR: Amyloidosis is not a single disease but a term for diseases that share a common feature: the extracellular deposition of pathologic insoluble fibrillar proteins in organs and tissues.
Journal ArticleDOI

The Alzheimer's Disease-Associated Amyloid β-Protein Is an Antimicrobial Peptide

TL;DR: The findings suggest Aβ is a hitherto unrecognized AMP that may normally function in the innate immune system and stands in stark contrast to current models of Aβ-mediated pathology and has important implications for ongoing and future AD treatment strategies.
Related Papers (5)
Trending Questions (1)
Amyloid-β peptide protects against microbial infection in mouse and worm models of Alzheimer’s disease

The paper provides evidence that amyloid-β peptide (Aβ) expression protects against fungal and bacterial infections in mouse and worm models of Alzheimer's disease.